While treatment with the GLP-1 receptor agonist did not impact the average drinks per calendar day or the number of drinking days, it significantly lowered the number of drinks per drinking day as well as weekly alcohol cravings
Reducing injection pain and discomfort Some people barely feel the needle
What's real and what's hype
Research applications Research applications In vitro receptor binding and signaling assays (MC4R/MC3R/MC1R)
Glucagon-like-peptide-1 receptor agonists (GLP-1s), including medications like Ozempic and Zepbound, have transformed weight management and treatment of chronic disease
Gabriel Bsteh: has participated in meetings sponsored by, received speaker honoraria or travel funding from Biogen, Celgene/BMS, Lilly, Merck, Novartis, Roche, Sanofi-Genzyme and Teva, and received honoraria for consulting Biogen, Celgene/BMS, Novartis, Roche, Sanofi-Genzyme and Teva